Literature DB >> 15261458

SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.

Noreen R Gonzales1, Eduardo A Padlan, Roberto De Pascalis, Peter Schuck, Jeffrey Schlom, Syed V S Kashmiri.   

Abstract

The humanization of mAbs by complementarity-determining region (CDR)-grafting has become a standard procedure to improve the clinical utility of xenogeneic Abs by reducing human anti-murine Ab (HAMA) responses elicited in patients. However, CDR-grafted humanized Abs may still evoke anti-V region responses when administered in patients. To minimize anti-V region responses, the Ab may be humanized by grafting onto the human templates only the specificity-determining residues (SDRs), the residues that are essential for the surface complementarity of the Ab and its ligand. Typically, humanization of an Ab, whether by CDR or SDR grafting, involves the use of a single human template for the entire VL or VH domain of an Ab. We hypothesized, however, that the homology between the human template sequences and mAb to be humanized may be maximized by using templates from multiple human germline sequences corresponding to the different segments of the variable domain. This could be more advantageous in reducing the potential immunogenicity of the humanized Ab. This report describes the SDR grafting of the murine anti-carcinoembryonic antigen (CEA) mAb COL-1 using three different human germline V-kappa sequences as templates for the VL CDRs and another human template for the VL frameworks. In competition RIAs, the SDR-grafted COL-1 (HuCOL-1SDR) completely inhibited the binding of radiolabeled murine COL-1 (mCOL-1) to CEA, and showed that its binding affinity is comparable to that of the CDR-grafted Ab (HuCOL-1). The HuCOL-1SDR showed similar binding reactivity to the CEA expressed on the surface of a tumor cell line as the HuCOL-1. More importantly, compared to HuCOL-1 and the "abbreviated" CDR-grafted Ab, HuCOL-1SDR showed lower reactivity to patients' sera carrying anti-V region Abs to mCOL-1. HuCOL-1SDR, which shows a lower sera reactivity than that of the parental Abs while retaining its Ag-binding property, is a potentially useful clinical reagent. To the best of our knowledge, this is the first time a VL or VH domain of an Ab has been humanized by grafting the SDRs onto a human template comprised of several Ab sequences. We have shown that humanization of an Ab can be optimized using multiple human templates for a single variable domain of an Ab. This approach maximizes the homology between the target Ab and the human templates in both the frameworks and the CDRs by choosing as the template the human sequence that displays the highest local sequence identity to the frameworks and to each of the CDRs of the target Ab.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261458     DOI: 10.1016/j.molimm.2004.03.041

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

Review 3.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

4.  Computationally driven antibody engineering enables simultaneous humanization and thermostabilization.

Authors:  Yoonjoo Choi; Christian Ndong; Karl E Griswold; Chris Bailey-Kellogg
Journal:  Protein Eng Des Sel       Date:  2016-06-21       Impact factor: 1.650

5.  Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.

Authors:  James R Apgar; Michelle Mader; Rita Agostinelli; Susan Benard; Peter Bialek; Mark Johnson; Yijie Gao; Mark Krebs; Jane Owens; Kevin Parris; Michael St Andre; Kris Svenson; Carl Morris; Lioudmila Tchistiakova
Journal:  MAbs       Date:  2016-09-13       Impact factor: 5.857

6.  Frontier of therapeutic antibody discovery: The challenges and how to face them.

Authors:  Zhi-Jian Lu; Su-Jun Deng; Da-Gang Huang; Yun He; Ming Lei; Li Zhou; Pei Jin
Journal:  World J Biol Chem       Date:  2012-12-26

7.  Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.

Authors:  Xinhui Wang; Akihiro Katayama; Yangyang Wang; Ling Yu; Elvira Favoino; Koichi Sakakura; Alessandra Favole; Takahiro Tsuchikawa; Susan Silver; Simon C Watkins; Toshiro Kageshita; Soldano Ferrone
Journal:  Cancer Res       Date:  2011-10-21       Impact factor: 12.701

8.  Phylogenetic discordance of human and canine carcinoembryonic antigen (CEA, CEACAM) families, but striking identity of the CEA receptors will impact comparative oncology studies.

Authors:  Marlene Weichselbaumer; Michael Willmann; Martin Reifinger; Josef Singer; Erika Bajna; Yuriy Sobanov; Diana Mechtcherikova; Edgar Selzer; Johann G Thalhammer; Robert Kammerer; Erika Jensen-Jarolim
Journal:  PLoS Curr       Date:  2011-03-16

9.  Structural consensus among antibodies defines the antigen binding site.

Authors:  Vered Kunik; Bjoern Peters; Yanay Ofran
Journal:  PLoS Comput Biol       Date:  2012-02-23       Impact factor: 4.475

10.  A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.

Authors:  Pascal Philibert; Audrey Stoessel; Wei Wang; Annie-Paule Sibler; Nicole Bec; Christian Larroque; Jeffery G Saven; Jérôme Courtête; Etienne Weiss; Pierre Martineau
Journal:  BMC Biotechnol       Date:  2007-11-22       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.